An Efficacy and Safety Study of Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva.
a study on Fibrodysplasia Ossificans Progressiva
Fibrodysplasia Ossificans Progressiva, Interventional study, Clinical trial phase 3, Efficacy and safety, Heterotopic ossification, Flare-up, Palovarotene, Retinoic acid receptor agonist, Retinoic acid receptor gamma agonist, Clementia, Myositis Ossificans Progressiva, Munchmeyer's Disease, FOP, FOP variants, Myositis Ossificans
Lead Scientist at UCSF
- Edward Hsiao
MD: MD, PhD, Johns Hopkins Medical School, 2001 Residency: Johns Hopkins Hospital, Baltimore, MD, Internal Medicine, 2001-2004 Fellowship: UCSF, Division of Diabetes, Endocrinology and Metabolism, 2004-2007 Board Certifications: Internal Medicine, 2004; Endocrinology and Metabolism, 2006 My research is driven by a desire to understand how major hormonal and regulatory pathways…
- in progress, not accepting new patients
- Start Date
- Completion Date
- Clementia Pharmaceuticals Inc.
- Website for the International FOP Association
- Phase 3 Fibrodysplasia Ossificans Progressiva Research Study
- Study Type
- Expecting 110 study participants
- Last Updated